Compare · ENOV vs ZBH
ENOV vs ZBH
Side-by-side comparison of Enovis Corporation (ENOV) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENOV and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $18.80B, about 12.4x ENOV ($1.51B).
- Over the past year, ENOV is down 7.6% and ZBH is down 1.2% - ZBH leads by 6.4 points.
- ZBH has been more active in the news (10 items in the past 4 weeks vs 5 for ENOV).
- ZBH has more recent analyst coverage (25 ratings vs 20 for ENOV).
- Company
- Enovis Corporation
- Zimmer Biomet Holdings Inc.
- Price
- $26.34-12.67%
- $97.21-0.94%
- Market cap
- $1.51B
- $18.80B
- 1M return
- +11.54%
- +11.00%
- 1Y return
- -7.63%
- -1.19%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 10
- Recent ratings
- 20
- 25
Enovis Corporation
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest ENOV
- SEC Form 10-Q filed by Enovis Corporation
- Enovis Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enovis Announces Second Quarter 2026 Results
- Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
- Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
- BMO Capital Markets initiated coverage on Enovis Corporation with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation
- Director Ortiz Christine was granted 846 shares, increasing direct ownership by 3% to 25,857 units (SEC Form 4)
- SEC Form 11-K filed by Enovis Corporation
- Chief Administrative Officer Engert Oliver bought $20,920 worth of shares (1,000 units at $20.92), increasing direct ownership by 2% to 53,640 units (SEC Form 4)
Latest ZBH
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by President, APAC Desai Chintan
- SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- Grp Pres-Global Business Thornal Kevin R converted options into 9,957 shares and covered exercise/tax liability with 4,266 shares (SEC Form 4) (tax liability)
- UBS initiated coverage on Zimmer Biomet with a new price target
- SEC Form 3 filed by new insider Desai Chintan
- Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
- Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results